Skip to main content
. Author manuscript; available in PMC: 2016 Oct 1.
Published in final edited form as: Clin Genitourin Cancer. 2015 May 16;13(5):453–460. doi: 10.1016/j.clgc.2015.05.003

Table 1. Study Regimen (TI-TIC).

Part Cycle number Number of Days per Cycle Dosage and Schedule
A 1–2b 14

  • Paclitaxel 200 mg/m2 IV over 3 hours on day 1

  • Ifosfamide 2000 mg/m2 IV over 4 hours daily, days 2–4 mixed 1:1 with mesna

  • G-CSF 10 mcg/kg/day SQ from day 3 until adequate collection or neutrophil recoverya

  • Leukapheresis daily from day 11 until day 14 or adequate stem cell collectionb
B 1–3 21–28

  • Paclitaxel 200 or 250 mg/m2 IV over 3 hours on day 1

  • Ifosfamide 2000 mg/m2 or 2667 mg/m2 or 3330 mg/m2 IV daily over 2–3 hours on days 1–3 (mixed 1:1 with mesna)

  • Carboplatin IV dosed to AUC of 7 or 8 over 1 hour daily, on days 1–3

  • Stem cell reinfusion (≥2×106 CD34+ cells/kg) on day 5

  • Pegylated-G-CSF 6 mg SQ, 6 hours after stem cell reinfusion on day 5

Abbreviations: G-CSF, granulocyte-colony stimulating factor; ANC, absolute neutrophil count; IV, intravenously; SQ, subcutaneously; AUC, area-under-the-curve

a

The first dose of G-CSF is administered 6 hours after completion of the ifosfamide infusion on day 3.

b

If adequate stem cell collection with cycle 1, cycle 2 is omitted